Aequus to launch trial for anti-nausea patch

Aequus Pharmaceuticals (CVE:AQS) said today that it won approval from Health Canada to launch a proof-of-concept trial to evaluate the bioavailability and safety of the company’s long-acting transdermal anti-nausea patch.

The device is made up of a combination of pyridoxine and doxylamine. The traditional form is delivered orally up to 4 times per day.

Get the full story at our sister site, Drug Delivery Business News.

The post Aequus to launch trial for anti-nausea patch appeared first on MassDevice.

from MassDevice http://ift.tt/2tJh7wU